ResMed completed acquisition of CMT, one of CID Fund II's portfolio companies

Oct 27, 2015

The CID Group (“CID”) is pleased to announce the completed acquisition of one of CID Greater China Venture Capital Fund II, L.P’s (“Fund”) portfolio companies, Curative Medical Technology. (“CMT or “the Company”) by ResMed Inc. (“ResMed”) (NYSE:RMD), a global leading provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories. As part of the merger transaction, CMT’s vascular catheter business is spin off from CMT and remain as Fund’s another portfolio company.

Read more X

Stock price of NPC, one of Fund III's portfolio companies, surged more than 50% above the listing price on the first day of listing

Jun 26, 2015

On the first day of trading, the Company’s stock price surged more than 50% above its listing price of NTD91 and closed at NTD139.95. The closing market cap reached NT3.08 billion (US$99 million)

Read more X

The CID Group Closes CID Greater China Fund V at US$ 150M, with 50% GP commitment

May 15, 2015

The CID Group today announced the close of CID Greater China Fund V (“Fund” or “CID IV”), a US$150M fund primarily focuses on the proprietary investment and industry integration opportunities in China and Taiwan. The Fund received strong backing from repeat investors of previous funds, including sovereign investment funds, endowments, financial institutions and family trusts, and completed the fundraising in only 4 months.

Read more X